{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:29:44Z","timestamp":1791224984804,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1016\/j.beha.2009.10.005","type":"journal-article","created":{"date-parts":[[2009,12,2]],"date-time":"2009-12-02T10:19:00Z","timestamp":1259749140000},"page":"315-329","source":"Crossref","is-referenced-by-count":16,"title":["Interferon in chronic myeloid leukaemia: past and future"],"prefix":"10.1016","volume":"22","author":[{"given":"Fran\u00e7ois","family":"Guilhot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Jean","family":"Saulnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2009.10.005_bib1","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukaemia-specific P210 protein is the product of the bcr\/abl hybrid gene","volume":"233","author":"Ben-Neriah","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.beha.2009.10.005_bib2","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.beha.2009.10.005_bib3","doi-asserted-by":"crossref","first-page":"10152","DOI":"10.1073\/pnas.95.17.10152","article-title":"T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukaemia after allogeneic stem cell transplantation","volume":"95","author":"Smit","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2009.10.005_bib4","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood.V82.8.2310.2310","article-title":"Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukaemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose","volume":"82","author":"Drobyski","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib5","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1182\/blood.V76.12.2462.2462","article-title":"Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients","volume":"76","author":"Kolb","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib6","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","article-title":"Graft-versus-leukaemia effect of donor lymphocyte transfusions in marrow grafted patients","volume":"86","author":"Kolb","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib7","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0042-6822(84)90105-3","article-title":"Various human interferon alpha subclasses cross-react with common receptors: their binding affinities correlate with their specific biological activities","volume":"132","author":"Aguet","year":"1984","journal-title":"Virology"},{"key":"10.1016\/j.beha.2009.10.005_bib8","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1099\/0022-1317-66-5-1149","article-title":"125I-labelled human interferons alpha, beta and gamma: comparative receptor-binding data","volume":"66","author":"Merlin","year":"1985","journal-title":"J Gen Virol"},{"key":"10.1016\/j.beha.2009.10.005_bib9","first-page":"2489","article-title":"Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons","volume":"58","author":"Pfeffer","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2009.10.005_bib10","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1073\/pnas.91.4.1198","article-title":"Cytokine therapeutics: lessons from interferon alpha","volume":"91","author":"Gutterman","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2009.10.005_bib11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0300-9084(99)80017-0","article-title":"The role of interferon regulatory factors in the interferon system and cell growth control","volume":"80","author":"Harada","year":"1998","journal-title":"Biochimie"},{"key":"10.1016\/j.beha.2009.10.005_bib12","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1126\/science.284.5421.1835","article-title":"The nature of the principal type 1 interferon-producing cells in human blood","volume":"284","author":"Siegal","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.beha.2009.10.005_bib13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/08830180109056724","article-title":"Transcription factors that regulate growth and differentiation of myeloid cells","volume":"20","author":"Nagamura-Inoue","year":"2001","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.beha.2009.10.005_bib14","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.4049\/jimmunol.156.10.3711","article-title":"Expression of IFN regulatory factor family proteins in lymphocytes. Induction of Stat-1 and IFN consensus sequence binding protein expression by T cell activation","volume":"156","author":"Nelson","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.beha.2009.10.005_bib15","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1073\/pnas.87.10.3743","article-title":"An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes","volume":"87","author":"Driggers","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2009.10.005_bib16","doi-asserted-by":"crossref","first-page":"25589","DOI":"10.1016\/S0021-9258(19)74081-2","article-title":"Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes","volume":"267","author":"Weisz","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.beha.2009.10.005_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.V91.1.22","article-title":"Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukaemias","volume":"91","author":"Schmidt","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib18","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1182\/blood.V97.11.3648","article-title":"Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukaemia correlates with pretreatment risk features and cytogenetic response to interferon-{alpha}","volume":"97","author":"Schmidt","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib19","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1128\/MCB.20.4.1149-1161.2000","article-title":"Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukaemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder","volume":"20","author":"Hao","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.beha.2009.10.005_bib20","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1182\/blood-2003-01-0291","article-title":"ICSBP\/IRF-8 inhibits mitogenic activity of p210 Bcr\/Abl in differentiating myeloid progenitor cells","volume":"102","author":"Tamura","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0092-8674(00)81348-3","article-title":"Immunodeficiency and chronic myelogenous leukaemia-like syndrome in mice with a targeted mutation of the ICSBP gene","volume":"87","author":"Holtschke","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.beha.2009.10.005_bib22","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1182\/blood.V97.11.3491","article-title":"Expression of interferon consensus sequence binding protein induces potent immunity against BCR\/ABL-induced leukaemia","volume":"97","author":"Deng","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib23","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/ni736","article-title":"Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology","volume":"2","author":"Asselin-Paturel","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.beha.2009.10.005_bib24","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1084\/jem.20021263","article-title":"ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8 alpha(+) dendritic cells","volume":"196","author":"Schiavoni","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.beha.2009.10.005_bib25","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1200\/JCO.1995.13.9.2401","article-title":"Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukaemia","volume":"13","author":"Sacchi","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2009.10.005_bib26","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/sj.leu.2402602","article-title":"Interferon-alpha induces dendritic cell differentiation of CML mononuclearcells in vitro and in vivo","volume":"16","author":"Paquette","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.10.005_bib27","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/sj.leu.2400919","article-title":"Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon","volume":"12","author":"Oka","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.10.005_bib28","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukaemia","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukaemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib30","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib31","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/sj.leu.2404609","article-title":"Chronic myeloid leukaemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies","volume":"21","author":"Jiang","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.10.005_bib32","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nature07815","article-title":"IFNalpha activates dormant haematopoietic stem cells in vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.beha.2009.10.005_bib33","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nm.1973","article-title":"Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion","volume":"15","author":"Sato","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.beha.2009.10.005_bib34","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1023668705040","article-title":"Apoptosis and interferons: role of interferonstimulated genes as mediators of apoptosis","volume":"8","author":"Chawla-Sarkar","year":"2003","journal-title":"Apoptosis"},{"key":"10.1016\/j.beha.2009.10.005_bib35","doi-asserted-by":"crossref","first-page":"15623","DOI":"10.1073\/pnas.95.26.15623","article-title":"Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays","volume":"95","author":"Der","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2009.10.005_bib36","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood.V89.3.957","article-title":"Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia","volume":"89","author":"Selleri","year":"1997","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2009.10.005_bib37","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10428199609074370","article-title":"Influence of interferon-alpha on cytokine expression by the bone marrow microenvironment\u2014impact on treatment of myeloproliferative disorders","volume":"22","author":"Peschel","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2009.10.005_bib38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/10428199809092680","article-title":"The effect of interferon-alpha on beta-1 integrin mediated adhesion and growth regulation in chronic myelogenous leukemia","volume":"28","author":"Bhatia","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2009.10.005_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3109\/10428199309047884","article-title":"Potential mechanisms of action of interferon-alpha in CML","volume":"11","author":"Dowding","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2009.10.005_bib40","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V69.5.1280.1280","article-title":"Clinical investigation of human alpha interferon in chronic myelogenous leukemia","volume":"69","author":"Talpaz","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib41","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood.V87.8.3069.bloodjournal8783069","article-title":"Treatment of chronic myelogenous leukemia: current status and investigational options","volume":"87","author":"Kantarjian","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/10428199309148513","article-title":"Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies","volume":"9","author":"Niederle","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2009.10.005_bib43","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1182\/blood.V82.10.2975.2975","volume":"82","author":"Ozer","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib44","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood.V72.2.642.642","article-title":"Interferon alpha-2b as therapy for Ph-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration","volume":"72","author":"Alimena","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib45","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1365-2141.1989.tb07715.x","article-title":"Recombinant human interferon(IFN) alpha-2b in chronic myelogenous leukemia. Dose dependency of response and frequency of neutralizing anti-interferon antibodies","volume":"72","author":"Freund","year":"1989","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2009.10.005_bib46","doi-asserted-by":"crossref","first-page":"736","DOI":"10.7326\/0003-4819-121-10-199411150-00002","article-title":"Low doses of Interferon-* are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia","volume":"121","author":"Schofield","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.beha.2009.10.005_bib47","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","article-title":"Randomized comparison of interferon-a with busulfan and hydroxyurea in chronic myelogenous leukemia (CML)","volume":"84","author":"Hehlmann","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib48","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0140-6736(95)92596-1","article-title":"UK Medical Research Council randomized, multicentre trial of interferon-a n1 for chronic myeloid leukemia: improved survival irrespective of cytogenetic response","volume":"345","author":"Allan","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2009.10.005_bib49","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V86.3.906.906","article-title":"A randomized trial comparing interferon-a with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase","volume":"86","author":"Ohnishi","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib50","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJM199403243301204","article-title":"Interferon-a-2b compared with conventional chemotherapy for the treatment of chronic myeloid leukemia","volume":"330","author":"Italian Cooperative Group on Chronic Myeloid Leukemia","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2009.10.005_bib51","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.V92.5.1541","article-title":"Long-term follow-up of the Italian trial of interferon-a versus conventional chemotherapy in chronic myeloid leukemia","volume":"92","author":"Italian Cooperative Study Group on Chronic Myeloid Leukemia","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib52","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1182\/blood.V91.8.2713.2713_2713_2721","article-title":"Randomized study on hydroxyurea alone versus hydroxyurea combined with low dose interferon-alpha2b for chronic myeloid leukemia","volume":"91","author":"The Benelux CML Study Group","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib53","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/sj.leu.2403006","article-title":"Randomized comparison of interferon a and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon a and hydroxyurea","volume":"17","author":"Hehlmann","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.10.005_bib54","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/89.21.1616","article-title":"Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta analysis of seven randomized trials","volume":"89","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.beha.2009.10.005_bib55","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0145-2126(88)90110-5","article-title":"Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia","volume":"12","author":"Sokal","year":"1988","journal-title":"Leukemia Res"},{"key":"10.1016\/j.beha.2009.10.005_bib56","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/10428199109107057","article-title":"Cytogenetic remissions in chronic myelogenous leukemia using interferon alpha2a and hydroxyurea with or without low dose cytosine-arabinoside","volume":"4","author":"Guilhot","year":"1991","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2009.10.005_bib57","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1200\/JCO.1992.10.5.772","article-title":"Treatment of advanced stages of Philadelphia chrosomome-positive chronic myelogenous leukemia with Interferon-* and low-dose cytarabine","volume":"10","author":"Kantarjian","year":"1992","journal-title":"J Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2009.10.005_bib58","article-title":"Interferon alpha (IFN-A) and low-dose cytosine arabinoside (Ara-C) therapy in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML)","volume":"86","author":"Kantarjian","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1056\/NEJM199707243370402","article-title":"Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia","volume":"337","author":"Guilhot","year":"1997","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.beha.2009.10.005_bib60","article-title":"Follow-up of 1047 patients with chronic myelogenous leukemia treated with interferon or interferon with cytarabine","volume":"90","author":"Guilhot","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib61","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood.V99.5.1527","article-title":"A randomized study of interferon-* and low-dose arabinosyl cytosine in chronic myeloid leukemia","volume":"99","author":"Baccarani","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib62","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0145-2126(02)00223-0","article-title":"A randomized study comparing interferon (IFNa) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)","volume":"27","author":"K\u00fchr","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2009.10.005_bib63","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/sj.leu.2402433","article-title":"Results of a phase II trial of a combination or oral cytarabine ocfosfate (YNK01) and interferon-*2b for treatment of chronic myelogenous leukemia patients in chronic phase","volume":"16","author":"Maloisel","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.10.005_bib64","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/sj.leu.2402850","article-title":"A phase II study of a-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia","volume":"17","author":"Rosti","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.10.005_bib65","first-page":"1281","article-title":"Interferona plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon","volume":"86","author":"Cervantes","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2009.10.005_bib66","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0145-2126(00)00036-9","article-title":"Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): a pilot study","volume":"24","author":"K\u00fchr","year":"2000","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2009.10.005_bib67","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.10.005_bib68","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood-2004-08-3373","article-title":"Punish the parent not the progeny","volume":"105","author":"Lucy","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib69","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/10428190601175393","article-title":"Phase II, randomized, multicenter, comparative study of peginterferon alfa-2a(40 KD) versus interferon alfa -2a (Roferon\u00ae-A) in patients with treatment-na\u00efve, chronic-phase chronic myelogenous leukemia","volume":"48","author":"Lipton","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2009.10.005_bib70","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.leu.2403217","article-title":"Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study","volume":"18","author":"Michallet","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2009.10.005_bib71","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood-2004-03-0826","article-title":"Imatinib an pegylated human recombinant interferon-\u03b12b in early chronic-phase chronic myeloid leukemia","volume":"104","author":"Baccarani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib72","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3324\/haematol.12265","article-title":"Front line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-\u03b1: 5 year outcome","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2009.10.005_bib73","first-page":"3512a","article-title":"PEGIntron and STI571 combination evaluation study (PISCES) in chronic phase chronic myelo\u00efd leukemia","volume":"98","author":"O'Brien","year":"2001","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2009.10.005_bib74","first-page":"0478","article-title":"Randomized clinical trial for the optimization of Imatinib therapy by combination, dose escalation and transplantation. Designed first interim analysis of the German CML study IV","volume":"94","author":"Hehlmann","year":"2009","journal-title":"Haematologica"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2009.10.005_bib75","first-page":"1093","volume":"94","author":"Rousselot","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2009.10.005_bib76","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.leukres.2007.06.008","article-title":"Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenetic response after interferon-alpha results in a very high complete molecular response rate","volume":"32","author":"Alimena","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2009.10.005_bib77","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-\u03b1 a study complete cytogenetic responders","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2009.10.005_bib78","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2004-10-4003","article-title":"Differential regulation of the p70 S6 kinase pathway by interferon \u03b1 (IFN\u03b1) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells","volume":"106","author":"Parmar","year":"2005","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692609000759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T19:11:43Z","timestamp":1685214703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692609000759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S1521692609000759"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2009.10.005","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}